title: Effect of serum phosphate on parathyroid hormone secretion during hemodialysis.
abstract: BACKGROUND
  Recent studies have demonstrated that a high concentration of phosphate directly stimulates parathyroid hormone (PTH) secretion. High serum levels of phosphate are usually observed in patients with end-stage renal disease. The aim of the present study was to evaluate whether serum phosphate concentration had an acute effect on PTH secretion in hemodialysis patients. The levels of serum phosphate were manipulated during the hemodialysis session by using a phosphate free dialysate or a dialysate with a high content of phosphate.
  
  
  METHODS
  Ten stable hemodialysis patients with PTH values above 300 pg/ml were included in the study. A PTH-calcium curve was obtained during both high phosphate and phosphate free hemodialysis.
  
  
  RESULTS
  The serum phosphate concentration remained high (2.17 +/- 0.18 mM) throughout the high phosphate hemodialysis and decreased progressively to normal levels (1.02 +/- 0.06 mM) during the phosphate free hemodialysis. The serum PTH levels at maximal inhibition by hypercalcemia (minimal PTH) were greater during the high phosphate than the phosphate free hemodialysis (413 +/- 79 vs. 318 +/- 76 pg/ml, P < 0.003). In all patients the values of minimum PTH were greater during the high phosphorus than the phosphorus free hemodialysis. The values of maximally stimulated PTH during hypocalcemia and the set point of the PTH-calcium curve were similar during the high phosphate and the phosphate free hemodialysis.
  
  
  CONCLUSIONS
  The maintenance of high serum phosphorus levels during hemodialysis prevented, in part, the inhibition of PTH secretion by calcium, which strongly suggests that in hemodialysis patients high serum phosphate contributes directly to the elevation of PTH levels despite normal or high serum calcium concentration.
authors.affiliation: Nephrology and Endocrinology Division, Hospital Universitario Valdecilla, Santander, Cordoba, Spain. martinal@medi.unican.es
authors.forename: A L
authors.initials: AL
authors.lastname: de Francisco
authors.forename: M A
authors.initials: MA
authors.lastname: Cobo
authors.forename: M A
authors.initials: MA
authors.lastname: Setien
authors.forename: E
authors.initials: E
authors.lastname: Rodrigo
authors.forename: G F
authors.initials: GF
authors.lastname: Fresnedo
authors.forename: M T
authors.initials: MT
authors.lastname: Unzueta
authors.forename: J A
authors.initials: JA
authors.lastname: Amado
authors.forename: J C
authors.initials: JC
authors.lastname: Ruiz
authors.forename: M
authors.initials: M
authors.lastname: Arias
authors.forename: M
authors.initials: M
authors.lastname: Rodriguez
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015314:Dialysis Solutions / Q000737:chemistry; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000097:blood; D008297:Male; D008875:Middle Aged; D009994:Osmolar Concentration; D010281:Parathyroid Hormone / Q000097:blood / Q000378:metabolism*; D010710:Phosphates / Q000008:administration & dosage / Q000097:blood* / Q000627:therapeutic use; D012016:Reference Values; D006435:Renal Dialysis
chemical_list: D015314:Dialysis Solutions; D010281:Parathyroid Hormone; D010710:Phosphates